Zentalis Pharmaceuticals Files 8-K on Bylaw Amendments, Fiscal Year Change
Ticker: ZNTL · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1725160
Sentiment: neutral
Topics: corporate-governance, 8-K-filing, bylaw-amendment, fiscal-year-change
Related Tickers: ZNTL
TL;DR
**ZNTL filed an 8-K about corporate charter changes and a fiscal year shift, but the filing is too brief to know the details.**
AI Summary
Zentalis Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, reporting events that occurred on February 12, 2024. The filing indicates amendments to its Articles of Incorporation or Bylaws and a change in its fiscal year. Additionally, the report mentions Financial Statements and Exhibits, though specific details for any of these items are not provided in the excerpt.
Why It Matters
This 8-K signals potential shifts in Zentalis Pharmaceuticals' corporate governance or financial reporting calendar. However, without the specific details of the amendments or the new fiscal year, the actual impact on investors or operations remains unknown.
Risk Assessment
Risk Level: low — The provided text only indicates the *type* of events reported (bylaw amendments, fiscal year change) without any specific details, making it impossible to assess any inherent risks from this excerpt alone.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — registrant
- United States Securities and Exchange Commission (company) — regulator
- 03 Life Sciences (company) — organization name associated with filer
FAQ
What is the accession number for this 8-K filing?
The accession number for this 8-K filing is 0001725160-24-000057.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is February 12, 2024.
What items are reported in this 8-K filing?
The filing reports "Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year" and "Financial Statements and Exhibits."
What is the Central Index Key (CIK) for Zentalis Pharmaceuticals, Inc.?
The Central Index Key (CIK) for Zentalis Pharmaceuticals, Inc. is 0001725160.
What is the business address of Zentalis Pharmaceuticals, Inc.?
The business address of Zentalis Pharmaceuticals, Inc. is 10275 Science Center Drive, Suite 200, San Diego, CA 92121.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-02-15 16:12:34
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
Filing Documents
- zntl-20240212.htm (8-K) — 35KB
- zntl-arbylawsxlwdraft2724x.htm (EX-3.1) — 282KB
- 0001725160-24-000057.txt ( ) — 517KB
- zntl-20240212.xsd (EX-101.SCH) — 2KB
- zntl-20240212_def.xml (EX-101.DEF) — 4KB
- zntl-20240212_lab.xml (EX-101.LAB) — 29KB
- zntl-20240212_pre.xml (EX-101.PRE) — 16KB
- zntl-20240212_htm.xml (XML) — 3KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 12, 2024, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the "Company") approved and adopted amendments to the Company's Bylaws (as amended, the "Amended and Restated Bylaws"), which became effective the same day. Among other things, the amendments contained in the Amended and Restated Bylaws: Address the universal proxy rules adopted by the U.S. Securities and Exchange Commission, by clarifying that no person may solicit proxies in support of a director nominee other than the Board's nominees unless such person has complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including applicable notice and solicitation requirements. Streamline procedural mechanics and enhance disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company's proxy materials pursuant to Rule 14a-8 under the Exchange Act). Prohibit the submission by a proposing stockholder of more director nominees than the number of directors up for election. The Amended and Restated Bylaws also incorporate certain technical, modernizing, clarifying and conforming changes. The foregoing description of the Amended and Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Bylaws of Zentalis Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: February 15, 2024 By: /s/ Melissa Epperly Melissa Epperly Chief Financial Officer